Search results
Results From The WOW.Com Content Network
During tissue typing, a number of HLA genes should be typed in both the donor and recipient, including HLA Class I A, B, and C genes, as well as HLA Class II DRB1, DRB3, DRB4, DRB5, DQA1, DQB1, DPA1, and DPB1 genes. [6] HLA typing is made more difficult by the fact that the HLA region is the most genetically variable region in the human genome. [7]
Myelophthisic anemia (also known as myelophthisis) is a severe kind of anemia found in some people with diseases that affect the bone marrow. Myelophthisis is the displacement of hemopoietic bone-marrow tissue into the peripheral blood, [51] either by fibrosis, tumors or granulomas. Neuroacanthocytosis: 29707: D054546
Myelophthisic anemia (or myelophthisis) is a severe type of anemia found in some people with diseases that affect the bone marrow. Myelophthisis refers to the displacement of hemopoietic bone-marrow tissue [1] by fibrosis, tumors, or granulomas. The word comes from the roots myelo-, which refers to bone marrow, and phthisis, shrinkage or atrophy.
The more aggressive forms of disease require treatment with chemotherapy, radiotherapy, immunotherapy and—in some cases—a bone marrow transplant. The use of rituximab has been established for the treatment of B-cell–derived hematologic malignancies, including follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). [7]
Other pre-existing bone-marrow disorders such as acquired aplastic anemia following immunosuppressive treatment and Fanconi anemia can evolve into MDS. [ 15 ] MDS is thought to arise from mutations in the multipotent bone-marrow stem cell , but the specific defects responsible for these diseases remain poorly understood.
Platelets <100×10 9 /L (thrombocytopenia) Neutrophils <1×10 9 /L (neutropenia) High blood levels of triglycerides (fasting, greater than or equal to 265 mg/100 ml) and/or decreased amounts of fibrinogen in the blood (≤ 150 mg/100 ml) Ferritin ≥ 500 ng/ml; Haemophagocytosis in the bone marrow, spleen or lymph nodes
The proposed criteria for SPB is the presence of a single bone lesion, normal bone marrow (less than 5% plasma cells), small or no paraprotein, no related organ involvement/damage and a normal skeletal survey (other than the single bone lesion). The criteria for extramedullary plasmacytoma are the same but the tumor is located in soft tissue.
MPNs arise when precursor cells (blast cells) of the myeloid lineages in the bone marrow develop somatic mutations which cause them to grow abnormally. There is a similar category of disease for the lymphoid lineage, the lymphoproliferative disorders acute lymphoblastic leukemia, lymphomas, chronic lymphocytic leukemia and multiple myeloma. [4]